Westborough, MA, United States
Westborough, MA, United States

Time filter

Source Type

Patent
Rxi Pharmaceuticals Corporation | Date: 2016-04-14

The present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal and fibrotic applications.


Patent
Rxi Pharmaceuticals Corporation | Date: 2015-04-28

Aspects of the invention relate to methods for treating cancer by administering to a subject in need thereof a therapeutically effective amount of a nucleic acid molecule that is directed against a gene encoding mouse double minute 1 homolog (MDM1), mouse double minute 2 homolog (MDM2), mouse double minute 3 homolog (MDM3), mouse double minute 4 homolog (MDM4) or V-myc myelocytomatosis viral related oncogene (MYCN) for treating cancer. Further aspects of the invention relate to nucleic acid molecules and compositions comprising nucleic acid molecules.


Aspects of the invention relate to methods for treating an ocular disorder associated with the front of the eye, comprising administering to the eye of a subject in need thereof a therapeutic RNA molecule, in an effective amount to treat an ocular disorder associated with the front of the eye.


Patent
Rxi Pharmaceuticals Corporation | Date: 2015-06-02

The present invention relates to methods for in vivo administration of sd-rxRNA molecules.


Patent
Rxi Pharmaceuticals Corporation | Date: 2015-06-02

The present invention relates to ocular administration of sd-rxRNA and rxRNAori molecules.


Patent
Rxi Pharmaceuticals Corporation | Date: 2015-06-02

RNAi constructs directed to MAP4K4 that demonstrate unexpectedly high gene silencing activities, and uses thereof are disclosed. The blunt-ended constructs have a double-stranded region of 19-49 nucleotides. The constructs have selective minimal modifications to confer an optimal balance of biological activity, toxicity, stability, and target gene specificity. For example, the strands may be modified (e.g., one or both ends of the sense strand is modified by 2-O-methyl groups), such that the construct is not cleaved by Dicer or other RNAse III, the antisense strand may also be modified by a 2-O-methyl group at the penultimate 5-end nucleotide to greatly reduce off-target silencing.


Patent
Rxi Pharmaceuticals Corporation | Date: 2015-12-02

The present invention relates to RNAi constructs with minimal double-stranded regions, and their use in gene silencing. RNAi constructs associated with the invention include a double stranded region of 8-14 nucleotides and a variety of chemical modifications, and are highly effective in gene silencing.


Patent
Rxi Pharmaceuticals Corporation | Date: 2016-02-11

The present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal applications.


Patent
Rxi Pharmaceuticals Corporation | Date: 2014-12-04

The present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal and fibrotic applications. Aspects of the invention provide nucleic acid molecules for the prophylactic treatment of wounding to reduce scarring. Herein, it is demonstrated that a specific nucleic acid molecule, RXI-109 (targeting connective tissue growth factor (CTGF)), given prophylactically, reduces scarring during wound healing.


Patent
Rxi Pharmaceuticals Corporation | Date: 2015-09-25

The present invention relates to RNAi constructs with minimal double-stranded regions, and their use in gene silencing. RNAi constructs associated with the invention include a double stranded region of 8-14 nucleotides and a variety of chemical modifications, and are highly effective in gene silencing.

Loading Rxi Pharmaceuticals Corporation collaborators
Loading Rxi Pharmaceuticals Corporation collaborators